Patient disposition
Of 125 patients screened, a total of 83 patients were randomized and treated in the study (i.e., ITT population): 27 patients in the SAR200 + 26W taper group, 14 patients in the SAR150 + 26W taper group, 28 patients in the PBO + 52W taper group, and 14 patients in the PBO + 26W taper group (Fig. Patient disposition. Of the 83 patients, only 36 were randomized prior to 16 Oct 2019 and were included in the week 52 analysis set: 13 patients in the SAR200 + 26W taper group, 7 patients in the SAR150 + 26W taper group, 10 patients in the PBO + 52W taper group, and 6 patients in the PBO + 26W taper group. Of these 36 patients, 29 completed the 52-week treatment period (8 patients in the SAR200 + 26W taper group, 6 patients each in the SAR150 + 26W and PBO + 26W taper groups, and 9 patients in the PBO + 52W taper group).